Showing 17,641 - 17,660 results of 17,926 for search '(( significant inverse decrease ) OR ( significant ((a decrease) OR (nn decrease)) ))', query time: 0.60s Refine Results
  1. 17641

    Kappa coefficients for different algorithms. by Yingying Liu (360782)

    Published 2025
    “…The research focuses on the advantages and problems of residual networks and depth-wise separable convolution modules, designs a new remote sensing image change detection model, and finally sets up experiments for verification. …”
  2. 17642

    The structure of ASPP+ block. by Yingying Liu (360782)

    Published 2025
    “…The research focuses on the advantages and problems of residual networks and depth-wise separable convolution modules, designs a new remote sensing image change detection model, and finally sets up experiments for verification. …”
  3. 17643

    The structure of attention gate block [31]. by Yingying Liu (360782)

    Published 2025
    “…The research focuses on the advantages and problems of residual networks and depth-wise separable convolution modules, designs a new remote sensing image change detection model, and finally sets up experiments for verification. …”
  4. 17644

    ZIKV infection enriches the HLA Class I pathway in brain tumour cells. by Matt Sherwood (22530221)

    Published 2025
    “…Normalised enrichment score (NES) denotes the degree to which the enrichment increased (+) or decreased (-). GSEA analysis significance is defined by p ≤ 0.05 and FDR ≤ 0.25. …”
  5. 17645

    DataSheet1_Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing.pdf by Seungchan An (6256061)

    Published 2024
    “…Subcutaneous injection of humanized CXCL12 Ab significantly delayed AA onset in mice, and dorsal skin was analyzed. …”
  6. 17646

    Table1_Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing.xlsx by Seungchan An (6256061)

    Published 2024
    “…Subcutaneous injection of humanized CXCL12 Ab significantly delayed AA onset in mice, and dorsal skin was analyzed. …”
  7. 17647

    Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  8. 17648

    Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  9. 17649

    Image 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”
  10. 17650

    Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  11. 17651

    Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  12. 17652

    Image 5_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”
  13. 17653

    Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  14. 17654

    Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  15. 17655

    Image 8_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  16. 17656

    Image 6_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  17. 17657

    Image 4_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tif by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  18. 17658

    Image 7_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff by Chao-Chao Chen (21090215)

    Published 2025
    “…<p>The global prevalence of metabolic diseases, including hypertension, type 2 diabetes mellitus (T2DM), gout, and obesity, has significantly increased over the past two decades. The brain plays a central role in regulating both human behavior and metabolism. …”
  19. 17659

    Table 4_The benefits and risks of adding PD-1/PD-L1 inhibitors to chemotherapy for stage IIIb-IV non-small-cell lung cancer: an updated meta-analysis based on phase 3 randomized co... by Yun Xu (139234)

    Published 2025
    “…The most common AEs in the PC group were blood toxicity related AEs (anemia, neutrophil count decreased, etc).</p>Conclusion<p>The PC therapy continues to provide a substantial survival benefit for patients with stage IIIb-IV NSCLC. …”
  20. 17660

    DataSheet1_Efferocytosis dysfunction in CXCL4-induced M4 macrophages: phenotypic insights in systemic sclerosis in vitro and in vivo.docx by Erwan Le Tallec (19834785)

    Published 2024
    “…Additionally, circulating levels of CXCL4, a novel SSc biomarker, correlate with more severe fibrotic manifestations of the disease. …”